Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer.

Prior treatment

• Prior treatment with surgery or radiation therapy for their target lesion(s)
• Prior laser at the tumour site
• Any ongoing treatment for malignancy, or in the last 4 weeks prior to study entry

Other illness

• Basal cell naevus syndrome, xeroderma, vitiligo and albinism
• Malignant melanoma systemic therapy ongoing
• Clinical concern of metastatic disease

Other

• Inability to personally provide written informed consent or to understand and collaborate throughout the study
• Inability or unwillingness to comply with study requirements
• Depth of lesion greater than 3mm as defined by Biopsy and/or clinical assessment
• Lupus and Scleroderma
• A tumour affecting nerves or bony structures
• Pregnancy and/or Lactation
• Pathological exclusions: Perineural Invasion, Lymphovascular invasion
• Anatomical exclusions: NMSC's of the Medial canthus, eyelid margin (upper and lower), Vermillion lip

• Stage I or II BCC or SCC (SCC Well to Moderately Differentiated), and clinically node negative disease
• Confirmed Histology, and with depth of lesion noted
• Subjects with up to 3 lesions suitable to enter the study (subjects with more than 3 lesions are not excluded from the study, however 3 target lesions are determined for study evaluation only.)
• Subjects able and willing to comply with the requirements of the study
• Age \>=18 years
• Informed Consent signed by the subject consenting to undergo the study
• Lesions up to 8cm2
• Lesions with a depth up to 3mm confirmed on biopsy report AND deemed appropriate clinically by treating clinician
• Subjects who are not deemed suitable for surgery, for example due to tumour location, performance status or other comorbidities as deemed relevant by the treating clinician
• Patients who may have declined Surgery and/or fractionated Radiation Therapy